Inhibrx Biosciences, Inc. (INBX)vsModerna Inc (MRNA)
INBX
Inhibrx Biosciences, Inc.
$99.61
-0.79%
HEALTHCARE · Cap: $1.63B
MRNA
Moderna Inc
$198.88
+2.08%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
INBX leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
INBX
Avoid21
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INBX.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$198.88
$64.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 11.7x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INBX
The strongest argument for INBX centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : INBX
The primary concerns for INBX are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
INBX profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
INBX carries more volatility with a beta of 3.67 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
INBX generates stronger free cash flow (-30M), providing more financial flexibility.
Bottom Line
INBX scores higher overall (21/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Inhibrx Biosciences, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?